{"title":"Designing halogen-free metal–phenolic imidazolium poly(ionic liquids) with multi-functional antibacterial, anti-inflammatory and cell proliferation properties for infected wounds","authors":"Danni Wang, Xiaodong He, Yingcui Cai, Chengju Sheng, Yuexiao Jia, Xiaojia Huang, Jia Ling Celestine Loh, Ruzhi Zhang, Mingmei Yang, Liqun Xu and Chao Zhou","doi":"10.1039/D5MD00612K","DOIUrl":null,"url":null,"abstract":"<p >Infected wounds are challenging to heal because they are complicated by bacterial infections, persistent inflammation, and impaired cell proliferation. Recently, imidazolium poly(ionic liquids) (PILs), as highly effective antibacterial agents, have been developed for infected wound healing. However, traditional imidazolium-based PILs containing halogen groups have shown potential cytotoxicity. In this study, we designed halogen-free metal–phenolic imidazolium PILs (HMPIPs) with antibacterial, anti-inflammatory and cell proliferation properties. Firstly, poly(vinyl-butylimidazolium dihydroxyphenylpropionic acid) (PVD) was synthesized <em>via</em> radical polymerization, anion exchange, and catechol deprotection. Subsequently, the HMPIPs were individually coordinated with metals ions (Zn<small><sup>2+</sup></small>, Mg<small><sup>2+</sup></small>, Cu<small><sup>2+</sup></small>, and Fe<small><sup>3+</sup></small>). The results indicated that PVD@Zn could form stable MPIP microparticles. <em>In vitro</em> assays revealed that PVD@Zn exhibited potent antibacterial activity against <em>Escherichia coli</em> (MIC: 512 μg mL<small><sup>−1</sup></small>) and <em>Staphylococcus aureus</em> (MIC: 128 μg mL<small><sup>−1</sup></small>), likely due to the synergistic effects of the imidazolium group's positive charge. Additionally, PVD@Zn exhibited anti-inflammatory effects by suppressing reactive oxygen species (ROS) and nitric oxide (NO) levels, and downregulating TNF-α, IL-1β, IL-6, and iNOS through Zn<small><sup>2+</sup></small>-mediated regulation. Notably, it enhanced L929 fibroblast proliferation by 22% <em>via</em> upregulation of amino acid biosynthesis pathways. <em>In vivo</em> assays further demonstrated that PVD@Zn significantly accelerated wound closure (97% contraction within 11 days), effectively reduced bacterial load (93% eradication), and exhibited minimal systemic organ toxicity. The multifunctional HPIPs, PVD@Zn, demonstrated antibacterial, anti-inflammatory, and pro-proliferative properties, potentially reducing the risk of drug overuse during wound healing. This system holds promise for future clinical application as an encapsulated therapeutic agent.</p>","PeriodicalId":88,"journal":{"name":"MedChemComm","volume":" 12","pages":" 6031-6040"},"PeriodicalIF":3.5970,"publicationDate":"2025-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"MedChemComm","FirstCategoryId":"1085","ListUrlMain":"https://pubs.rsc.org/en/content/articlelanding/2025/md/d5md00612k","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 0
Abstract
Infected wounds are challenging to heal because they are complicated by bacterial infections, persistent inflammation, and impaired cell proliferation. Recently, imidazolium poly(ionic liquids) (PILs), as highly effective antibacterial agents, have been developed for infected wound healing. However, traditional imidazolium-based PILs containing halogen groups have shown potential cytotoxicity. In this study, we designed halogen-free metal–phenolic imidazolium PILs (HMPIPs) with antibacterial, anti-inflammatory and cell proliferation properties. Firstly, poly(vinyl-butylimidazolium dihydroxyphenylpropionic acid) (PVD) was synthesized via radical polymerization, anion exchange, and catechol deprotection. Subsequently, the HMPIPs were individually coordinated with metals ions (Zn2+, Mg2+, Cu2+, and Fe3+). The results indicated that PVD@Zn could form stable MPIP microparticles. In vitro assays revealed that PVD@Zn exhibited potent antibacterial activity against Escherichia coli (MIC: 512 μg mL−1) and Staphylococcus aureus (MIC: 128 μg mL−1), likely due to the synergistic effects of the imidazolium group's positive charge. Additionally, PVD@Zn exhibited anti-inflammatory effects by suppressing reactive oxygen species (ROS) and nitric oxide (NO) levels, and downregulating TNF-α, IL-1β, IL-6, and iNOS through Zn2+-mediated regulation. Notably, it enhanced L929 fibroblast proliferation by 22% via upregulation of amino acid biosynthesis pathways. In vivo assays further demonstrated that PVD@Zn significantly accelerated wound closure (97% contraction within 11 days), effectively reduced bacterial load (93% eradication), and exhibited minimal systemic organ toxicity. The multifunctional HPIPs, PVD@Zn, demonstrated antibacterial, anti-inflammatory, and pro-proliferative properties, potentially reducing the risk of drug overuse during wound healing. This system holds promise for future clinical application as an encapsulated therapeutic agent.
期刊介绍:
Research and review articles in medicinal chemistry and related drug discovery science; the official journal of the European Federation for Medicinal Chemistry.
In 2020, MedChemComm will change its name to RSC Medicinal Chemistry. Issue 12, 2019 will be the last issue as MedChemComm.